|1.||Borchert, Hans-Hubert: 2 articles (07/2012 - 01/2010)|
|2.||Baspinar, Yücel: 2 articles (07/2012 - 01/2010)|
|3.||Wollenberg, Andreas: 2 articles (01/2012 - 01/2010)|
|4.||Chow, Melody: 2 articles (09/2004 - 07/2004)|
|5.||Gupta, Aditya K: 2 articles (09/2004 - 07/2004)|
|6.||Korting, H C: 2 articles (07/2004 - 05/2003)|
|7.||Schäfer-Korting, M: 2 articles (07/2004 - 05/2003)|
|8.||Ruiz-González, Inmaculada: 1 article (07/2015)|
|9.||Pérez-Bustillo, Alicia: 1 article (07/2015)|
|10.||Rodríguez-Prieto, Manuel-Ángel: 1 article (07/2015)|
|1.||Atopic Dermatitis (Atopic Eczema)
07/01/2001 - "In conclusion, this study found prednicarbate emollient cream 0.1% to be safe and effective for the treatment of atopic dermatitis in pediatric patients for up to 3 weeks."
06/01/1997 - "Evaluation of skin layer-specific prednicarbate (PC) biotransformation, possibly explaining the improved benefit/risk ratio of this topical corticosteroid in atopic dermatitis (1,2). "
07/01/2001 - "A multicenter, 3-week, open-label study evaluated prednicarbate emollient cream 0.1%, a nonhalogenated midpotency corticosteroid, in 55 patients aged 4 months to 12 years who were diagnosed with atopic dermatitis. "
01/04/2010 - "A physically and chemically stable positively charged prednicarbate nanoemulsion was developed as a carrier system for the treatment of atopic dermatitis. "
12/01/2004 - "Thus, prednicarbate may be a consideration in the treatment of atopic dermatitis in children, and other inflammatory disorders in children and adults."
06/01/2008 - "If a flare occurred, defined as an exacerbation (unacceptable severity of itching/scratching or onset of oozing) not controlled by study medication, patients were treated with prednicarbate 0.25% cream instead. "
04/01/2006 - "Silver textiles reduced the severity of the pruritus (p = 0.031); silver-free textiles (n.s.) and prednicarbate (n.s.) were less effective. "
01/01/1998 - "Prednicarbate is indicated for relief of inflammation and pruritus associated with corticosteroid-responsive dermatological disorders such as dermatitis (eczema) [including atopic dermatitis] and psoriasis and can be used in children and elderly patients. "
09/01/2004 - "Prednicarbate has been found to have a favorable benefit-risk ratio, with low skin atrophy potential, and a high anti-inflammatory action. "
01/01/1992 - "0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream."
03/01/2002 - "Prednicarbate is a topical glucocorticoid with an improved benefit/risk ratio, as it causes less skin atrophy than the equipotent betamethasone 17-valerate."
03/01/2002 - "Visible signs of atrophy or telangiectasia were detected in two subjects each upon betamethasone 17-valerate and mometasone furoate, but not upon prednicarbate or its vehicle. "
01/01/1998 - "Therefore, prednicarbate is a useful option for the treatment of corticosteroid-responsive dermatoses and appears to have low atrophogenic potential when used without occlusion."
01/01/1986 - "[Photographic follow-up of the topical use of prednicarbate preparations in inflammatory dermatoses]."
11/15/1989 - "[Eczema diseases and erythemato-squamous dermatoses of aging skin--studies of the effectiveness and tolerance of Prednicarbate in various vehicles]."
12/01/2004 - "Prednicarbate is a nonhalogenated corticosteroid that is used in the treatment of inflammatory skin diseases, for example atopic dermatitis. "
11/15/1989 - "Prednicarbate, therefore, is especially suitable in the treatment of eczemas and chronic erythematosquamous dermatoses of aged skin."
|1.||Betamethasone 17-Valerate (Betamethasone 17 Valerate)
|6.||Adrenal Cortex Hormones (Corticosteroids)
|2.||Drug Therapy (Chemotherapy)